Literature DB >> 18194188

Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in a sickle cell disease patient.

Hugo H Davila1, Justin Parker1, J Christopher Webster1, Jorge L Lockhart1, Rafael E Carrion2.   

Abstract

INTRODUCTION: Ischemic priapism (IP) is a urologic condition, which necessitates prompt management. Intracavernosal injection of phenylephrine is a usual treatment modality utilized for the management of these patients. Aim. We present a case of subarachnoid hemorrhage following intracavernosal injection of phenylephrine for IP in a patient with sickle cell disease.
METHODS: We analyzed the degree of subarachnoid hemorrhage in our patient after intracavernosal injection of phenylephrine. The patient had an acute rise in blood pressure during corporal irrigation. This was followed by the onset of severe headache. Computed tomography (CT) scan confirmed the diagnosis of a subarachnoid hemorrhage. MAIN OUTCOME MEASURE: Subarachnoid hemorrhage associated with intracavernosal injection of phenylephrine. Result. A 23-year-old African American male with a history of sickle cell disease presented with a painful penile erection. The patient was started on intravenous fluids, oxygen by nasal canula, and analgesic medication. After this, a blood gas was obtained from his left corpora cavernosa. This was followed by normal saline irrigation and injection of phenylephrine. The patient complained of a sudden, severe "terrible headache" immediately following the last injection, and noncontrast CT scan of the head was obtained and a subarachnoid hemorrhage was noted. The patient was admitted for observation and no significant changes were noted.
CONCLUSIONS: Intracavernosal injection of phenylephrine for the management of IP can be associated with several possible complications. We present our single case complicated with the formation of a subarachnoid hemorrhage. The patient was treated conservatively and had no long-term neurologic sequelae. Davila HH, Parker J, Webster JC, Lockhart JL, and Carrion RE. Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in a sickle cell disease patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194188     DOI: 10.1111/j.1743-6109.2007.00715.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Intracerebral hemorrhage associated with oral phenylephrine use: a case report and review of the literature.

Authors:  Brian E Tark; Steven R Messe; Clotilde Balucani; Steven R Levine
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-08-23       Impact factor: 2.136

2.  A Case Report of Hypertensive Emergency and Intracranial Hemorrhage Due to Intracavernosal Phenylephrine.

Authors:  Raga Deepak Reddy Palagiri; Kshitij Chatterjee; Anusha Jillella; Drayton A Hammond
Journal:  Hosp Pharm       Date:  2018-05-29

Review 3.  Management of priapism: an update for clinicians.

Authors:  Helen R Levey; Robert L Segal; Trinity J Bivalacqua
Journal:  Ther Adv Urol       Date:  2014-12

4.  Selective enhancement of contractions to α1-adrenergic receptor activation in the aorta of mice with sickle cell disease.

Authors:  Ramiro Juncos; Luis Juncos; Robert P Hebbel; Gregory M Vercellotti; Zvonimir S Katusic; Karl A Nath
Journal:  J Cardiovasc Pharmacol       Date:  2011-02       Impact factor: 3.105

Review 5.  Review of Ischemic and Non-ischemic Priapism.

Authors:  Mark G Biebel; Martin S Gross; Ricardo Munarriz
Journal:  Curr Urol Rep       Date:  2022-05-10       Impact factor: 3.092

Review 6.  What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.

Authors:  S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze
Journal:  Int J Impot Res       Date:  2022-08-08       Impact factor: 2.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.